TICKERS: IMV; IMMVF

Analyst's 'Top Pick' Advances Vaccine Candidates
Research Report

Source:

Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus.

In a Nov. 10, 2017 research note, analyst Douglas Loe noted that Immunovaccine Inc. (IMV:TSX.V) "generated cumulative return of 37% since Echelon Wealth Partners' last update note. Immunovaccine is developing novel therapeutic and preventive vaccines for cancer and other serious diseases.

The report included updates on two of the company's DepoVax assets: DPX-Survivac and DPX-RSV.

For DPX-Survivac, the lipid-based, water-free injectable formulation of the cancer antigen survivin, enrollment is underway in several phase 1/2 studies. One is a 40-patient recurrent ovarian cancer study that combines DPX-Survivac with epacadostat, Incyte Corp.'s (INCY:NASDAQ) small-molecule indole 1,2-dioxygenase checkpoint inhibitor drug. "A second interim tumor response/immunological response update is expected later in FY Q4/17," Loe indicated.

Another Phase 1/2 trial is being conducted at Princess Margaret Hospital in Toronto. In this 42-patient, ovarian cancer study, DPX-Survivac is being combined with Keytruda (pembrolizumab), Merck's anti-PD monoclonal antibody drug. "Interim data from that trial [are] expected by mid-2018," Loe wrote.

In a third Phase 1/2 study, the same therapies, DPX-Survivac in combination with Keytruda (pembrolizumab), are being combined but in patients with diffuse large B-cell lymphoma. Sunnybrook Hospital in Toronto is currently enrolling 25 patients for it. Loe said interim tumor and immunological response data are likely in FY H2/18 at the earliest.

As for Immunovaccine's DPX-RSV, "development is advancing in the pipeline of a few firms, so we will be watching closely for Immunovaccine to advance DPX-RSV clinical activities imminently," Loe said. DPX-RSV is a small, B-cell epitope peptide vaccine targeting the unmet medical needs in respiratory syncytial virus (RSV).

The biotech is "actively seeking partnership interest" for the vaccine, Loe wrote. "The next steps in DPX-RSV will be expensive steps (large RSV infection avoidance studies, or perhaps even challenge studies, will need to be conducted in Phase 3), and so we agree with management's strategy to identify cash-contributing partners before investing its own capital in new DPX-RSV clinical initiatives," he added.

At the end of Q3/17, Immunovaccine had $16.6 million in cash, "corresponding [to an] existing operating loss run rate to about two years of cash," said Loe. However, development costs will likely rise, however, as the "DepoVax pipeline expands into other medical markets beyond oncology and infectious disease" and "existing programs advance into more substantive Phase 2 studies, perhaps as early as FY H2/18."

"YTD, IMV shares have generated strong returns of 125%, with 37% of this generated since our Top Pick update, and we see strong price appreciation potential on forthcoming DPX-Survivac clinical updates as described above, independent of any new pipeline advances that Immunovaccine may undertake during our forecast period. Our PT corresponds to a one-year return of 77%," Loe wrote.

Echelon has a Top Pick status, Speculative Buy recommendation and $2.75 per share price target on Immunovaccine, whose stock is currently trading at $1.63 per share.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.




Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe